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Abstract
Background: Vitamin A supplementation (VAS) given to children between 6 months and 5 years of age is known
to reduce mortality in low-income countries. We have previously observed that girls benefit more from a lower
dose of VAS than the one recommended by WHO, the effect being strongest if diphtheria-tetanus-pertussis
vaccine (DTP) was the most recent vaccination. We aimed to test these observations.
Methods: During national immunisations days in Guinea-Bissau, West Africa, combining oral polio vaccination and
VAS, we randomised 8626 children between 6 months and 5 years of age to receive the dose of VAS
recommended by WHO or half this dose. Mortality rate ratios (MRRs) were assessed after 6 and 12 month.
Results: The overall mortality rate among participants was lower than expected. There was no significant
difference in mortality at 6 months and 12 months of follow up between the low dose VAS group and the
recommended dose VAS group. The MRRs were 1.23 (0.60-2.54) after 6 months and 1.17 (0.73-1.87) after 12
months. This tendency was similar in boys and girls. The low dose was not associated with lower mortality in girls
if the most recent vaccine was DTP (MRR = 0.60 (0.14-2.50) after 6 months).
Conclusion: Our sample size does not permit firm conclusions since mortality was lower than expected. We could
not confirm a beneficial effect of a lower dose of VAS on mortality in girls.
Trial registration: The study was registered under clinicaltrials.gov, number NCT00168636
Background
Vitamin A supplementation (VAS) given to children
above 6 months of age may reduce overall mortality in
low-income countries by 23-30%[1-3]. The World
Health Organization (WHO) currently recommends
high-dose VAS at immunisation contacts after 6 months
of age. Children between 6 and 12 months are advised a
dose of 100,000 IU and children older than 12 months,
a dose of 200,000 IU; every 4 to 6 months [4].
The reduction in mortality is assumed to be due to
treatment and prevention of vitamin A deficiency
(VAD)[1]. However, this mayn o tb et h eo n l ye x p l a n a -
tion. Routine vaccines during childhood have been
shown to have non-specific effects on overall mortality
[5-9]. While the live BCG and measles vaccine seem to
confer protection against other diseases than the tar-
geted diseases [5-8], the inactivated diphtheria-tetanus-
pertussis (DTP) vaccine has been associated with
increased overall mortality in girls [5,9]. Our group
hypothesised that the effect of VAS on mortality may
depend on an amplification of the non-specific effects of
the vaccines [10]. If this is true, a high dose of vitamin
A would not necessarily be better than a low dose, espe-
cially for girls who were also receiving DTP.
Previous trials have in fact indicated that a lower dose
of vitamin A might be more beneficial than a higher
dose in reducing mortality [11,12] and morbidity [13].
O n eo ft h ef i r s tr a n d o m i s e dv i t a m i nAt r i a l su s e ds m a l l
weekly doses of vitamin A instead of a high-dose sup-
plement and that study found the strongest beneficial
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paring children who received 25,000 IU or 100,000 IU
of vitamin A at 9 months of age, those receiving the
lower dose had significantly lower mortality by 12
months of age [11]. In 2002, our group conducted a
trial during an oral polio vaccine (OPV) and VAS cam-
paign in Guinea-Bissau, randomising children between 6
months and 5 years of age to the dose recommended by
WHO and half that dose. We found that among girls
the low dose was associated with a significant reduction
in mortality at 6 and 9 months of follow-up [12]. This
difference was mainly seen in girls 18 month of age or
older [12] and in girls who had a DTP vaccine as their
most recent vaccine before the enrolment in the trial
(unpublished results).
We aimed to test the observations made in our former
trial by testing the ap r i o r ihypothesis that a lower dose
of vitamin A compared with the recommended dose is
associated with lower mortality in girls. We furthermore
hypothesised that the lower dose would be particularly
beneficial in girls who had DTP vaccine at their most
recent vaccination contact compared with girls who had
other vaccines.
Methods
Setting
In Guinea-Bissau, West Africa, the Bandim Health Pro-
ject (BHP) runs a health and demographic surveillance
system (HDSS) in six suburban districts of the capital
Bissau. There are three health centres in the study area.
Guinea-Bissau has one paediatric ward, situated a few
kilometres from the study area, where children are
admitted in case of severe illness. During the study per-
iod from November 2004-November 2005, the mortality
rate among 6-60-month-old children in the study area
was 0.012 and the stunting prevalence was 16%.
Up to the age of 3 years, all children in the study area
are visited by the BHP assistants every 3 months to
obtain information on vital status, hospitalisations, vac-
cinations, infections, etc. Older children are visited
approximately once per year. Information on vaccina-
tions is also registered by the BHP at the three health
centres and upon admission to the paediatric ward.
In Guinea-Bissau national immunisation days (NIDs)
are conducted regularly. In 2004, all children below 5
years of age were targeted in two OPV campaigns in
October and in November. In November all children
between 6 months and 5 years of age were also offered
VAS. The campaigns were carried out by staff from the
local health centres, who went from house to house pro-
viding the treatment to target children. In the study area
of the BHP, trained fieldworkers followed the campaign
staff from the local health centres with a list of all chil-
dren in the area generated from the HDSS database. All
fieldworkers were followed by a supervisor at least one
day during the campaign.
Ethical considerations
The trial was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the Central
Ethical Committee in Denmark and the Ministry of
Health’s Committee for research in Guinea-Bissau. Ver-
bal informed consent was obtained from the mother/
guardian of all children by the staff from the health cen-
tre and recorded by the field worker from the BHP.
Consent was verbal since more than 70% of the mothers
are illiterate. The purpose of the study was clearly
explained and by drawing a lot it was made clear that
they took part in a randomised study.
Enrolment and randomisation to two different doses of
VAS
Children between 6 months and 5 years of age residing
in the BHP study area in November 2004 were eligible
for enrolment in the present trial. Exclusion criteria
were 1) signs of clinical vitamin A deficiency, and 2)
VAS within the last month prior to the date of visit.
Randomisation envelopes were prepared prior to the
campaign. The envelopes contained 100 lots, 50 marked
“WHO” and 50 marked “BHP”.T h em o t h e r sw e r e
explained that vitamin A was given because it reduces
morbidity and mortality, but that there is no clear evi-
dence which dose is the best. If the mother agreed to
p a r t i c i p a t es h ed r e wal o tf r o mt h ee n v e l o p ei n d i c a t i n g
which dose of vitamin A her child should receive. If the
lot said “WHO”, the child would receive 100,000 IU if it
was younger than 1 year of age, and 200,000 IU if it was
1y e a ro ro l d e r .I ft h el o ts a i d“BHP” the dose would be
50,000 IU if the child was younger than 1 year of age,
and 100,000 IU if the child was 1 year or older. If the
mother did not want her child to participate, the child
was given the dose recommended by the WHO. The
vitamin A was distributed in gelatine capsules contain-
ing retinyl palmitate (International Dispensary Associa-
tion, The Netherlands).
The field workers and the participants were not
blinded to the randomisation. The child’s vaccination
card was inspected, existing information on vaccine sta-
tus was verified, and new vaccines noted on the list.
Outcomes
The main outcome was mortality after 6 and 12 months
of follow-up.
Trained fieldworkers visited all enrolled children after
6 months. There was no information about the alloca-
tion on the follow-up forms. Vital status was confirmed,
the child’s vaccination card was inspected, and new
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seen, information on vaccinations status was obtained
f r o mt h eH D S S .T h ed a t af r o mt h ec a m p a i g na n df r o m
the 6-month visit were double entered and controlled
by comparing the data with the information from the
HDSS.
Information on survival and vaccination status after 12
months of follow-up was obtained during the NIDs in
November 2005. We controlled the data entry by dou-
ble-entering 10% of the data, and found a 99.1% degree
of consistency. Furthermore, information on vital status
and dates of vaccinations was compared with informa-
tion from the HDSS. In case of inconsistency, informa-
tion was checked by visiting the household again.
If a child had died, a local doctor interviewed the
mother or guardian using a verbal autopsy questionnaire
[15]. A panel of three medical doctors, including at least
one local doctor, all blinded to the randomisation
group, reached consensus on the cause of death.
Participation in a neonatal VAS trial
In the period from August 2002 to November 2004, the
BHP conducted a trial randomising children to receive
vitamin A or placebo at birth together with BCG (the
“Vitamin-A-at-birth” trial)[16]. We linked our data to
the “Vitamin-A-at-birth” trial, also including children
from the preceding pilot study, which took place from
August 2002 to November 2002 to study whether VAS
at birth modified the response to the different doses
[17].
Non-participants
We compared trial participants with the children who
were eligible for enrolment, but were travelling during
the campaign or not participating for other reasons (Fig-
ure 1). We did not have a 6-month follow-up visit to
obtain information on survival and vaccination, but used
the HDSS data. This approach resulted in fewer children
i nt h eo l d e ra g eg r o u p sb e c a u s et h eH D S So n l yv i s i t s
children up to 3 years of age.
Samples size considerations
We aimed to recruit all eligible children in our study
area, hence including two more districts than in our
previous trial. We expected to be able to recruit
approximately 7500 children. With an expected mortal-
ity of 1.2% at 6 months of follow-up it would be possi-
ble to detect a 55% reduction in mortality among girls
who received the low dose compared with the recom-
mended dose within the first year with a power of 80%
and a two-sided significance level of 0.05. In the pre-
vious trial we had found the low dose to be associated
with a 72% reduction in female mortality after 9 months
[12].
Data analysis and statistical methods
Statistical analysis was conducted using Stata/SE 9.2
(Stata corporation, Texas, USA). The analyst was not
blinded to randomisation group while doing the ana-
lyses. Baseline characteristics were compared by chi^2-
tests and by t-tests. Mortality rate ratios (MRRs) were
computed in Cox proportional hazards models with
time since enrolment as the underlying time. Children
who died due to accidents were censored from the ana-
lyses at the time of the death. We tested for confound-
ing on the outcome death within 12 months of follow-
up by including background variables in the model one
by one, defining confounders as variables which changed
t h ee s t i m a t eb ym o r et h a n5 % .I na l la n a l y s e sc h i l d r e n
were censored if they received VAS during follow-up
(Figure 1). When analysing the effect of most recent
vaccination before the campaign, we censored children
when they received a vaccine during follow-up. As the
date of vaccination, we used the date of registration
instead of the actual day of vaccination to avoid survival
bias [18].
Results
Baseline characteristics
A total of 10702 children were eligible for randomisa-
tion. No children were excluded due to clinical signs of
VAD. Of the eligible children 8626 (80.6%) were
enrolled in the trial between November 18-21 2004. The
main reason for not being enrolled was travelling (1494
(14.0%)) of all eligible children) (Figure 1). Due to con-
flicting information between dose and age, 44 (0.5%)
children were excluded. A total of 4223 (49.2%) received
the WHO recommended dose and 4359 (50.8%)
received the low dose. The randomisation groups were
comparable with regard to sex, vaccination status and
socio-economic characteristics (Table 1). However, the
groups differed with regards to age distribution with
more children between 6 and 11 months of age being in
the low-dose group. As a consequence more children in
the low-dose group had also been enrolled in the “Vita-
min-A-at-birth” trial (Table 1). Adjusting for VAS-at-
birth did not change the estimate on overall mortality
by more than 5%, and final estimates were therefore
only adjusted for age.
Main analyses of mortality
Information on survival was obtained for all children at
6 months and 12 months of follow-up. A total of 73
children died within 12 months of follow-up. For two
children the death was due to an accident (1 male in
the high-dose group, and 1 female in the low-dose
group), and they were therefore censored in the analysis
at the time of death. The overall mortality rate (MR)
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person years at risk).
There was no significant difference in mortality at 6
months and 12 months of follow up between the low
dose VAS group and the recommended dose VAS
group; the MRR being 1.23 (0.60-2.54) after 6 months
and 1.17 (0.73-1.87) after 12 months. The MRRs did not
differ between boys and girls (Table 2).
Eligibility: 10702
Not enrolled during campaign:
8 refused to participate
1494 travelling
184 received VAS at another place
317 were absent
73 missing information 
Recommended dose: 4223
(2109M, 2114 F)
Low dose: 4359
(2260M, 2099F)
6-month visit:
173 moved
13 died (5M, 8F)
635 received VAS 
during follow-up
Total person years: 
1922
6-month visit:
159 moved
17 died (5M, 12F*)
*1 female death 
excluded due to 
accident
782 received VAS 
during follow-up
Total person years: 
1952
Non-participants: 2076 
(1018M, 1058F)
6-month visit:
477 moved
12 died (7M, 5F)
3 lost to follow-up
189 received VAS 
during follow-up
Total person years:
811
Excluded after randomisation:
44 lack of agreement between 
randomisation group and dose 
received
12-month visit:
478 moved
32 died (13M*, 19F)
*1 male death 
excluded due to 
accident
744 received VAS 
during follow-up
Total person years: 
3451
12-month visit:
442 moved
39 died (18M, 21F)
927 received VAS 
during follow-up
Total person years: 
3476
Randomised: 8626
12-month visit:
638 moved
27 died (14M, 13F)
3 lost to follow-up
260 received VAS 
during follow-up
Total person years: 
1429
Figure 1 Flow chart.
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Vitamin A
Low dose (%)
Vitamin A
High dose (%)
P-value
Low doses vs. High dose
Non-participants (%) P-value
Non-participants vs. Participants
Number 4359 4223 2076
Sex
Male 2260 (51.8) 2109 (50.0) 1018 (49.0)
Female 2099 (49.2) 2114 (50.0) 0.08 1058 (51.0) 0.13
Age (months)
6-11 661 (15.2) 513 (12.1) 330 (15.9)
12-17 510 (11.7) 478 (11.3) 289 (13.9)
18-35 1464 (33.6) 1463 (34.6) 677 (34.1)
36-60 1724 (39.5) 1769 (41.9) < 0.001 780 (37.6) < 0.001
Type of most recent vaccine
1
BCG/MV 1565 (35.9) 1492 (35.3) 704 (33.8)
DTP 2240 (51.4) 2186 (51.7) 0.94 988 (47.7) < 0.001
“Vitamin-A-at-birth” trial
VAS-at-birth 634 (50.7) 514 (49.2) 250 (45.6)
Placebo 617 (49.3) 530 (50.8) 0.04 298 (54.4) 0.06
District
Bandim 1927 (44.2) 1834 (43.4) 1018 (49.0)
Belem/Mindara 800 (18.3) 746 (17.7) 356 (17.2)
Cuntum 1632 (37.4) 1643 (38.9) 0.36 702 (33.8) < 0.001
Ethnic group
Pepel 1359 (30.2) 1289 (30.5) 603 (29.0)
Fula 634 (14.5) 623 (14.7) 404 (19.5)
Manjaco 553 (12.7) 569 (13.5) 228 (11.0)
Others 1813 (41.6) 1742 (41.3) 0.70 841 (40.5) < 0.001
Maternal education
3 (years)
0 1318 (30.2) 1255 (29.7) 800 (38.5)
1-4 706 (16.2) 707 (16.7) 345 (16.6)
5-6 699 (16.0) 654 (15.5) 269 (13.0)
≥ 7 1160 (26.6) 1147 (27.2) 0.87 396 (19.1) < 0.001
Maternal age
3 (years)
≤ 18 194 (4.5) 153 (3.6) 87 (4.2)
19-24 1237 (28.4) 1196 (28.3) 645 (31.1)
25-29 1168 (26.8) 1192 (28.2) 617 (29.7)
≥ 30 1366 (31.3) 1320 (31.3) 0.22 526 (25.3) < 0.001
Number of siblings
3
0-1 1399 (32.1) 1387 (32.8) 720 (34.7)
2-3 1703 (39.1) 1682 (39.8) 879 (42.3)
≥ 4 1068 (24.5) 986 (23.3) 0.48 414 (19.9) < 0.001
Type of roof
2
Straw 249 (5.7) 246 (5.8) 120 (5.8)
Zinc (hard) 3919 (89.9) 3803 (90.0) 0.85 1890 (91.0) 0.07
Electricity
2
No 2926 (67.1) 2868 (67.9) 1489 (71.7)
Yes 1240 (28.5) 1182 (28.0) 0.66 521 (25.1) < 0.001
1Of all participating and non-participating, 763 children received DTP+MV together, 720 not vaccinated or no information
2Information at time of childbirth, numbers do not add up due to missing information
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ferent depending on the most recent vaccination. After
6 months of follow-up, the MRR was 0.60 (0.14-2.50) if
the most recent vaccination was DTP and 3.06 (0.63-15)
if the most recent vaccine was BCG vaccine or measles
vaccine (p for same effect = 0.12). After 12 months the
estimates were 0.77 (0.29-2.07) and 1.21 (0.45-3.26)
respectively (p for same effect 0.55).
Causes of death
The cause of death was determined by verbal autopsy in
56 (77%) of the 73 dead children. Information on cause
of death from a brief interview made shortly after death
was available for 8 of the remaining 17 children. There
were no significant difference in cause of death between
the two randomisation groups (results not shown), but
there were too few deaths to allow for a meaningful
comparison; hence, the data mainly served to excluded
deaths due to accidents.
Post hoc analyses
There was no evidence that a lower dose was more ben-
eficial in girls above 18 months of age (Table 3). Pre-
vious studies have suggested limited beneficial effect of
micronutrient supplementation in girls below 12 months
of age [19]. In this study there was a tendency for the
lower dose being more beneficial in the youngest chil-
dren (p = 0.06 for same effect in children below and
above 12 months of age) which was not limited to girls
(Table 3).
We have recently observed that the mortality effect of
V A Sa t1 2m o n t h so fa g ew a ss i g n i f i c a n t l yd i f f e r e n ti n
females who had received VAS or placebo at birth [17].
In the present trial the response to the different doses
did not depend significantly on whether a child had
received VAS at birth (Table 3).
Comparison of participants and non-participants
There were notable differences in baseline characteris-
tics between participants and non-participants (Table
1). Adjusting for age and type of most recent vaccine
changed the estimate on overall mortality by more
than 5%, and all comparisons between participants and
non-participants were therefore adjusted for these
variables.
Among the non-participants 2073 (99.9%) children
could be followed for 1429 person years during 12
months. In this group 27 children died (MR = 0.019),
none of them due to accident (Figure 1). We found a
borderline significant reduction in mortality for those
who participated in the trial (MRR after 12 months of
follow-up: 0.64 (0.41-1.01)). For boys this reduction was
consistent and significant both after 6 months (MRR =
0.36 (0.13-0.94)) and 12 months of follow-up (MRR =
0.52 (0.28-0.99)), whereas for girls there was no signifi-
cant effect of participating, the MRRs after 6 and 12
months being 1.05 (0.39-2.84) and 0.77 (0.41-1.45),
respectively (p = 0.11 and p = 0.10 for same effect in
boys and girls after 6 and 12 months of follow-up,
respectively)(Figure 2).
Discussion
In our previous trial, the low dose of VAS was asso-
ciated with an overall MRR of 0.69 (0.36-1.35), based on
a strong beneficial effect in females (0.19 (0.06-0.66)
after 6 months of follow-up; 0.28 (0.11-0.70) after 9
months)[12]. This effect was particularly seen among
the older girls and girls who had DTP as their last vac-
cine. In the present trial, which was designed to test this
observation, we were not able to confirm the beneficial
effect of a lower dose of VAS on overall female mortal-
ity, nor did we confirm a significant beneficial effect of
the low dose among girls with DTP as their most recent
Table 2 Mortality after 6 and 12 months of follow-up in children who received a lower dose compared with the
recommended dose of vitamin A, Guinea-Bissau 2004-2005
All
(n = 8582)
Boys
(n = 4369)
Girls
(n = 4213)
At 6 months of follow-up Mortality Rate (deaths/years at risk)
Low dose 0.009 (17/1952) 0.005 (5/1005) 0.013 (12/947)
High dose 0.007 (13/1922) 0.005 (5/955) 0.008 (8/968)
Mortality Rate Ratio
1 (95% CI) 1.23 (0.60-2.54) 0.92 (0.27-3.17) 1.43 (0.59-3.51)
P for same effect in boys and girls 0.57
At 12 months of follow-up Mortality Rate (deaths/years at risk)
Low dose 0.011 (39/3476) 0.010 (18/1788) 0.012 (21/1688)
High dose 0.009 (32/3451) 0.008 (13/1714) 0.011 (19/1737)
Mortality Rate Ratio
1 (95% CI) 1.17 (0.73-1.87) 1.30 (0.64-2.65) 1.08 (0.58-2.02)
P for same effect in boy and girls 0.71
1 Adjusted for sex and age as a continuous variable
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dren below 12 months of age benefitted more from
receiving a lower dose. Compared with non-participants,
it was only boys, who benefited significantly from parti-
cipating in the campaign.
Strengths and weaknesses
Strengths of the present trial include the randomised
design and the large number of participants.
Weaknesses include that the two randomisation
groups differed in regard to age with an overweight of
younger children the low-dose group. This pattern was
consistent within the whole study area, and since the
fieldworkers were under supervision during the cam-
p a i g nt h i si sm o s tl i k e l yac h a n c ee v e n t .W ec o n t r o l l e d
all analyses for age, but cannot exclude that there are
other underlying differences between the two groups
which were not adjusted for.
Table 3 Mortality after 12 months of follow-up comparing a lower dose of vitamin A with the recommended dose
among subgroups
Number of deaths/years at risk Mortality Rate Ratio
1 (95% CI)
(Low dose vs. Recommended dose)
Low dose Recommended dose
All
(n = 8582)
All
(n = 8582)
Boys
(n = 4369)
Girls
(n = 4213)
Age groups
6-11 months 7/397 11/327 0.54 (0.21-1.38) 0.39 (0.07-2.11) 0.63 (0.20-1.99)
12-17 months 7/316 4/301 1.65 (0.48-5.63) 1.34 (0.30-6.00) 2.73 (0.28-26)
18-60 months 25/2763 17/2823 1.50 (0.81-2.77) 1.97 (0.74-5.25) 1.22 (0.54-2.72)
P for same effect in age groups 0.17 0.27 0.46
VAS at birth
All
(n = 2295)
All
(n = 2295)
Boys
(n = 1182)
Girls
(n = 1113)
VAS at birth 5/308 3/260 1.30 (0.31-5.46) 0.89 (0.05-15) 1.50 (0.27-8.18)
Placebo at birth 2/289 6/251 0.29 (0.06-1.41) 0.79 (0.05-13) 0.18 (0.02-1.52)
P for same effect by VAS at birth 0.17 0.93 0.12
1 Adjusted for sex and age as a continuous variable.
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Figure 2 Kaplan-Meier survival curves in boys and girls, comparing participants with non-participants.
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from participants with regard to many baseline character-
istics, indicating strong selection bias. We have attempted
to control for all known confounders, but the comparisons
between participants and non-participants should none-
theless be interpreted with great caution. Selection bias,
however, is unlikely to explain why only boys benefitted
significantly from participation in the study.
The trial was not blinded, but this is not likely to
affect an outcome like mortality.
Potential explanations for contrasting results
We explored the potential explanations for the lack of
consistency between our previous trial, which found a
strong beneficial effect of a low dose in girls, and the
present trial. Though our findings were based on small
numbers and not significant, post hoc analyses showed a
similar beneficial effect of the low dose in girls who had
been randomised to placebo at birth. In contrast, girls
who had received VAS at birth seemed to benefit more
from the higher dose. That neonatal VAS primes the
response to a subsequent dose of VAS is supported by a
recent observation within the “vitamin-A-at-birth"-trial.
In that trial girls who had received VAS at birth bene-
fitted significantly from receiving a high dose of vitamin
A at age 12 months compared with girls who had
received placebo at birth [17].
This could be a possible explanation for the divergent
results in the present trial and the previous 2002 trial;
in 2002 no children had received VAS at birth.
Sex-differences in the response to VAS
Many studies which analysed data by sex have found sex-
differences in the response to VAS [12,19-25]. Overall
sex-differences have not been confirmed in meta-analyses
[1-3], but it should be noted that the analyses by sex have
been based on a limited number of trials, since surpris-
ingly many have not reported data by sex, and further-
more the meta-analyses have not taken vaccination status
into account. The present trial did not clearly confirm
previous observations of sex-differences in response to
VAS. However, though the results were by no way signifi-
cant, as seen in the previous trial, girls tended to benefit
more from a lower dose of VAS if DTP was the most
recent vaccine than if the most recent vaccine was BCG
or measles vaccine. Furthermore, only boys benefitted
significantly from participating in the campaign. These
sex-difference may be due to a negative interaction
between VAS and DTP in girls [23-25].
Context
Our trial was done in a setting with a low prevalence of
clinical VAD. None of the 8626 children were excluded
from the trial due to clinical VAD. At 4 months of age
16% of the children in the study area had low levels of reti-
nol binding protein indicating VAD [26], and that figure
was 9% when controlled for CRP [26]. The impact of VAS
may be different in settings with a higher prevalence of
VAD.
Conclusions
In conclusion, we did not confirm the previously
observed effect of a lower dose of vitamin A being more
beneficial for girls at either 6 or 12 months of follow-up.
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